Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey

dc.authorscopusid56370690600
dc.authorscopusid56015193100
dc.authorscopusid8842895600
dc.authorscopusid57194114271
dc.authorscopusid25622225900
dc.authorscopusid23969004700
dc.authorscopusid57251124400
dc.contributor.authorDal M.S.
dc.contributor.authorMerdin A.
dc.contributor.authorErkurt M.A.
dc.contributor.authorEkinci Ö.
dc.contributor.authorAlbayrak M.
dc.contributor.authorHacıoglu S.K.
dc.contributor.authorKaya A.
dc.date.accessioned2024-08-04T20:00:47Z
dc.date.available2024-08-04T20:00:47Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage1539en_US
dc.identifier.issn1107-0625
dc.identifier.issue4en_US
dc.identifier.pmid34565016en_US
dc.identifier.scopus2-s2.0-85114520313en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1536en_US
dc.identifier.urihttps://hdl.handle.net/11616/91007
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMulticenteren_US
dc.subjectPeripheral T-cell lymphomaen_US
dc.subjectPralatrexateen_US
dc.titlePralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkeyen_US
dc.typeArticleen_US

Dosyalar